FLT3 Ligand Immunotherapy (CDX-301) and Stereotactic Radiotherapy for Advanced NSCLC
Non-small Cell Lung Cancer (NSCLC)
Enrolment: 33 · Results not recorded
Loading the evidence…
Biologic
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Non-small Cell Lung Cancer (NSCLC)
Enrolment: 33 · Results not recorded
Acute Myelogenous Leukemia (AML)
Enrolment: 36 · Results not recorded
Melanoma
Enrolment: 132 · Results not recorded
Breast Cancer
Enrolment: 100 · Results not recorded
Low-Grade B-cell Lymphoma
Enrolment: 21 · Results not recorded
Metastatic Castration-resistant Prostate Cancer
Enrolment: 43 · Results not recorded
Prostate Cancer
Enrolment: 27 · Results not recorded
HER2-negative Breast Cancer
Enrolment: 30 · Results not recorded
Healthy
Enrolment: 30 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Cobalt-60 gamma total body irradiation producing haematopoietic acute radiation syndrome; doses used included 7 Gy (myelosuppression), 9.25 Gy (LD70/30) and 8.0 to 10.5 Gy for dose reduction factor studies
A single subcutaneous dose of CDX-301 given from 24 h before to 24 h after total body irradiation significantly improved 30-day survival. Survival was not dose-dependent; 12 h and 24 h pre-irradiation dosing gave 100% survival, and 1600 ug/kg given 4 h after 9.25 Gy raised survival to 54% versus 22…
Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.